Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cyproheptadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 4/20 | 0.93 |
| ▸ | LMNA | P02545 | 3/20 | 0.97 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | MAPT | P10636 | 1/20 | 0.97 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.97 |
| ▸ | SETD7 | Q8WTS6 | 7/20 | 0.93 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.93 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.93 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.93 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.93 |
| ▸ | HTR1A | P08908 | 4/20 | 0.93 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.93 |
| ▸ | DRD1 | P21728 | 4/20 | 0.93 |
| ▸ | DRD3 | P35462 | 4/20 | 0.93 |
| ▸ | HTR2A | P28223 | 4/20 | 0.93 |
| ▸ | HTR2C | P28335 | 4/20 | 0.93 |
| ▸ | HTR2B | P41595 | 4/20 | 0.93 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.93 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyproheptadine SCHEMBL27756503 | 1.00 | LMNA (0.97) | LMNAMEN1MAPTPMP22KMT2A | |
| Cyproheptadine SCHEMBL30772122 | 0.98 | LMNA (1.00) | LMNAMEN1MAPTPMP22KMT2A | |
| Cyproheptadine SCHEMBL29380652 | 0.98 | LMNA (1.00) | LMNAMEN1MAPTPMP22KMT2A | |
| Cyproheptadine SCHEMBL20610743 | 0.98 | LMNA (1.00) | LMNAMEN1MAPTPMP22KMT2A | |
| Cyproheptadine SCHEMBL5500354 | 0.98 | LMNA (1.00) | LMNAMEN1MAPTPMP22KMT2A | |
| Cyproheptadine SCHEMBL41842 | 0.98 | LMNA (1.00) | LMNAMEN1MAPTPMP22KMT2A | |
| Cyproheptadine SCHEMBL7923153 | 0.96 | SETD7 (1.00) | LMNAMEN1MAPTPMP22KMT2A | |
| Cyproheptadine SCHEMBL4021 | 0.96 | SETD7 (1.00) | LMNAMEN1MAPTPMP22KMT2A | |
| Cyproheptadine SCHEMBL29369949 | 0.96 | SETD7 (1.00) | LMNAMEN1MAPTPMP22KMT2A | |
| Cyproheptadine SCHEMBL28514693 | 0.95 | SETD7 (0.90) | LMNAMEN1MAPTPMP22KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12582606-B2 | Tablet and method for producing tablet | SUNSHO PHARMACEUTICAL CO., LTD. (JP) | 2026-03-24 | — | — | US | disclosed |
| US-20240016745-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2024-01-18 | — | — | US | disclosed |
| EP-4260847-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2023-10-18 | — | — | EP | disclosed |
| WO-2023282283-A1 | COMPOSITION FOR IMPROVING ORAL ENVIRONMENT | 明治ホールディングス株式会社 | 2023-01-12 | — | — | WO | disclosed |
| CN-112552230-B | Synthetic method of cyproheptadine hydrochloride | 佛山普正医药科技有限公司 | 2022-08-26 | — | — | CN | disclosed |
| US-20220218616-A1 | TABLET AND METHOD FOR PRODUCING TABLET | SUNSHO PHARMACEUTICAL CO., LTD. (JP) | 2022-07-14 | — | — | US | disclosed |
| CN-112552230-A | Synthetic method of cyproheptadine hydrochloride | 佛山普正医药科技有限公司 | 2021-03-26 | — | — | CN | disclosed |
| EP-2465539-B1 | DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET | FUJI CHEM IND CO LTD (JP) | 2018-07-11 | — | — | EP | disclosed |
| EP-2465540-B1 | DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET | FUJI CHEM IND CO LTD (JP) | 2016-10-05 | — | — | EP | disclosed |
| US-9446055-B2 | Disintegrating particle composition and orally rapidly disintegrating tablet | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2016-09-20 | — | — | US | disclosed |
| EP-3023109-A1 | ORALLY DISINTEGRATING TABLET | Sanwa Kagaku Kenkyusho Co., Ltd (JP) | 2016-05-25 | — | — | EP | disclosed |
| US-20160136091-A1 | Orally Disintegrating Tablet | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2016-05-19 | — | — | US | disclosed |
| CN-105377303-A | Orally disintegrating tablet | SANWA KAGAKU KENKYUSHO CO | 2016-03-02 | — | — | CN | disclosed |
| US-8900602-B2 | Disintegrating particle composition and orally rapidly disintegrating tablet | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2014-12-02 | — | — | US | disclosed |
| US-20120165413-A1 | DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20120156261-A1 | DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2012-06-21 | — | — | US | disclosed |
| EP-2465539-A1 | DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2012-06-20 | — | — | EP | disclosed |
| EP-2465540-A1 | DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2012-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12582606-B2 | Tablet and method for producing tablet | GRHPR, RCC1, KIT | HRH1 301/4885LMNA 2295/4885MEN1 3180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.